Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results
- PMID: 22302962
- DOI: 10.2967/jnumed.111.094235
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results
Abstract
Radioembolization of liver cancers using (90)Y-loaded microspheres is experiencing more widespread use. However, few data are available concerning the doses delivered to the tumors and the healthy liver. This retrospective study was conducted to calculate the tumor dosimetry (planned tumor dose [T(plan) D]) and nontumor dosimetry in patients treated by (90)Y-loaded glass microspheres and determine whether tumor dosimetry could predict response and survival.
Methods: Thirty-six patients with hepatocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-loaded glass microspheres. The T(plan) D and the dose delivered to the injected healthy liver were calculated using a quantitative analysis of the (99m)Tc-macroaggregated albumin ((99m)Tc-MAA) SPECT/CT exam. Responses were assessed after 3 mo, using the criteria of the European Association for the Study of the Liver. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier tests.
Results: The response rate was 69% for the overall population and 75% for the PVT patients. The dose delivered to the tumor was the only parameter associated with response with multivariate analysis (P = 0.019). A threshold T(plan) D value of 205 Gy was predictive of response, with a sensitivity of 100% and an accuracy of 91%. Quantitative (99m)Tc-MAA SPECT/CT allowed us to increase the injected activity for 4 patients with large lesions. PFS was only 5.2 mo and OS 9 mo when using a T(plan) D of less than 205 Gy versus 14 mo (P = 0.0003) and 18 mo (P = 0.0322), respectively, with a T(plan) D of 205 Gy or more.
Conclusion: Quantitative (99m)Tc-MAA SPECT/CT is predictive of response, PFS, and OS. Dosimetry based on (99m)Tc-MAA SPECT/CT can be used for the selection of patients and for an adaptation of treatment planning, especially in selected patients (particularly in the case of large tumors). These results also confirm the efficacy and safety of (90)Y-loaded microspheres in treating HCC, even in the presence of PVT (and especially when (99m)Tc-MAA uptake is seen inside the PVT).
Similar articles
-
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.J Nucl Med. 2015 Mar;56(3):339-46. doi: 10.2967/jnumed.114.145177. Epub 2015 Feb 12. J Nucl Med. 2015. PMID: 25678490
-
A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007. J Vasc Interv Radiol. 2014. PMID: 24461133
-
Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.Nucl Med Commun. 2015 Apr;36(4):340-9. doi: 10.1097/MNM.0000000000000257. Nucl Med Commun. 2015. PMID: 25563137
-
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75. doi: 10.1007/s00259-015-3157-8. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26338177 Free PMC article. Review.
-
90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry.Semin Nucl Med. 2019 May;49(3):218-226. doi: 10.1053/j.semnuclmed.2019.01.006. Epub 2019 Feb 7. Semin Nucl Med. 2019. PMID: 30954188 Review.
Cited by
-
Radiomics-Based Prediction Model for Outcome of Radioembolization in Metastatic Colorectal Cancer.Cardiovasc Intervent Radiol. 2024 Apr;47(4):462-471. doi: 10.1007/s00270-024-03680-6. Epub 2024 Feb 28. Cardiovasc Intervent Radiol. 2024. PMID: 38416178
-
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial.J Nucl Med. 2024 Feb 1;65(2):264-269. doi: 10.2967/jnumed.123.266211. J Nucl Med. 2024. PMID: 38212068 Free PMC article. Clinical Trial.
-
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):947-950. doi: 10.1007/s00259-023-06568-8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38110711 Free PMC article. No abstract available.
-
Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma.Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):245-257. doi: 10.1007/s00259-023-06416-9. Epub 2023 Sep 12. Eur J Nucl Med Mol Imaging. 2023. PMID: 37698645 Free PMC article.
-
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.Cancers (Basel). 2023 Aug 26;15(17):4274. doi: 10.3390/cancers15174274. Cancers (Basel). 2023. PMID: 37686549 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical